Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, ...

Serplulimab is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC; Serplulimab is the first and only anti-PD-1 mAb approved in th ...

Development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad spectrum activity designed to address the urgent ...

Sun Pharma maintained market leadership, while Emcure and Torrent advanced to 10th and 16th positions, respectively. Top performers included Alkem, Aristo, Intas, Torrent, Cipla, and FDC, all ...

Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software ...

RALEIGH, N.C., Jan. 16, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of ...

SAN FRANCISCO, Jan 16 (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for president-elect Donald Trump and Congress on ...

Pfizer and Intel have sent warnings to the European Chemicals Agency which is considering the move Pfizer pharmaceuticals wrote that a total ban would threaten the viability of this sector.

and serving as Vice President for Intas Pharmaceuticals Ltd. His career spans over two decades, marked by significant contributions to revenue growth and market expansion in the pharmaceutical sector.

Detailed price information for Sunshine Biopharma (SBFM-Q) from The Globe and Mail including charting and trades.

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

For Fierce Pharma's day 1 news roundup, click here. Fierce Biotech's day 1 coverage can be found here. Below, check out the latest coverage from day 2, including a wrap-up of the scene outside of ...